Table of Contents Author Guidelines Submit a Manuscript
Journal of Thyroid Research
Volume 2010, Article ID 325602, 4 pages
Research Article

Prognostic Outcomes of Tall Cell Variant Papillary Thyroid Cancer: A Meta-Analysis

1Department of Otolaryngology, Head and Neck Surgery, Boston University School of Medicine, 820 Harrison Avenue, FGH4, Boston MA 02118, USA
2Department of Otolaryngology, University of Connecticut, Farmington, CT 06262, USA
3Department of Biostatistics, Boston University School of Public Health, Boston, MA 02118, USA

Received 17 January 2010; Accepted 24 June 2010

Academic Editor: David Goldenberg

Copyright © 2010 Scharukh Jalisi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Objective. To evaluate the prognosis of tall cell variant (TCV) compared to usual variant (UV) papillary thyroid cancer by comparing disease-related mortality and recurrence data from published studies. Methods. Ovid MEDLINE keyword search using “tall cell variant papillary thyroid cancer” was used to identify studies published in English that calculated disease-related mortality and recurrence rates for both TCV and UV. Results. A total of 131 cases of tall cell variant papillary thyroid cancer were reviewed. The combined odds ratio of recurrence for TCV compared to UV is 4.50 with a 95% confidence interval from 2.90 to 6.99. For disease-related mortality, the combined odds ratio for TCV was compared to UV of 14.28 with a 95% confidence interval from 8.01 to 25.46. Conclusion. Currently published data suggests that TCV is a negative prognostic indicator in papillary thyroid cancer and requires aggressive therapy. This meta-analysis provides the largest prognostic data series on TCV in the literature and clearly identifies the need for accurate pathological identification of TCV and its further study as an independent prognostic factor.